Copper chelation pathway

The "Copper chelation pathway" is not a single molecular target but rather refers to the collection of biological processes and mechanisms by which organisms regulate the uptake, distribution, utilization, storage, and excretion of copper ions. In humans and other organisms, this involves a network of transporters (such as human copper transporter 1 [hCTR1]), chaperones (metallochaperones), storage proteins (metallothioneins), enzymes that utilize copper as a cofactor (e.g., cytochrome c oxidase), as well as efflux pumps like ATP7A/ATP7B that maintain cellular and systemic homeostasis.[3] Copper chelation therapy uses small molecules—chelators—that bind free or loosely bound copper ions with high affinity. This approach is clinically important in treating disorders associated with abnormal accumulation or toxicity of copper such as Wilson’s disease or certain neurodegenerative conditions. Chelators can also be used experimentally to study the role of labile ("free") pools of Cu+ or Cu2+ in cell biology.[2] In cancer research, disrupting tumor-promoting pathways dependent on elevated intracellular copper has been explored using specific chelators.[5] In microbiology, natural products called chalkophores produced by bacteria/fungi act as environmental scavengers for essential metals including copper; some have antimicrobial properties due to their ability to sequester toxic metal concentrations.[4] Because "Copper chelation pathway" describes an entire regulatory system rather than a discrete protein/receptor/enzyme/transporter molecule typically considered a drug target—and because it lacks specificity—it should not be classified as an individual therapeutic target. If you need structured information about specific components within this system—such as "human high-affinity copper uptake protein 1" (hCTR1/SLC31A1) or "ATPase Cu++ transporting beta polypeptide"—please specify the particular molecule. In summary: > The term “Copper chelation pathway” refers broadly to physiological mechanisms controlling cellular/organismal handling of the essential trace element **copper** via binding/removal by endogenous proteins or exogenous drugs. It is not itself a canonical molecular drug target but encompasses multiple targets involved in metal ion transport/homeostasis relevant for various diseases including cancer and neurodegeneration.[1][2][3][4][5]

Other names

Copper chelationCopper homeostasis pathwayCopper metabolism pathway

Chelation and removal of excess copper ions from tissues or circulation to restore normal copper levels and reduce toxicity or oxidative stress